Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy. This is an ASCO Meeting Abstract from the 2023 ...
Ten years after a milestone victory, AI now dominates Go training. Players are figuring out what that means for the game.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results